• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    ZimVie Reports First Quarter 2025 Financial Results

    5/8/25 4:05:00 PM ET
    $ZIMV
    Medical/Dental Instruments
    Health Care
    Get the next $ZIMV alert in real time by email
    • Net Sales from Continuing Operations of $112.0 million
    • Net Loss from Continuing Operations of $(2.6) million; Net Loss margin of (2.3)%
    • Adjusted EBITDA[1] from Continuing Operations of $17.6 million; Adjusted EBITDA[1] margin of 15.7%
    • GAAP diluted EPS from Continuing Operations of $(0.09) and adjusted diluted EPS[1] from Continuing Operations of $0.27

    PALM BEACH GARDENS, Fla., May 08, 2025 (GLOBE NEWSWIRE) -- ZimVie Inc. (NASDAQ:ZIMV), a global life sciences leader in the dental market, today reported financial results for the quarter ended March 31, 2025. Management will host a corresponding conference call today, May 8, 2025, at 4:30 p.m. Eastern Time.

    "We are proud to have entered 2025 with a strong focus on execution and operational diligence as we maintain a leading position with dental customers through innovation and education," said Vafa Jamali, President and Chief Executive Officer. "Going forward, we intend to advance our goal to drive operational efficiency and profitability improvements while striving towards a return to top-line growth."

    First Quarter 2025 Financial Results: Continuing Operations

    Net sales for the first quarter of 2025 were $112.0 million, a decrease of 5.2% on a reported basis and 4.1% in constant currency[1], versus the first quarter of 2024.

    Net loss for the first quarter of 2025 was $(2.6) million, an improvement of $8.9 million versus a net loss of $(11.5) million in the first quarter of 2024. Net loss margin for the first quarter of 2025 was (2.3)% of net sales, an improvement of 740 basis points versus a net loss margin of (9.7)% in the first quarter of 2024.

    Adjusted net income[1] for the first quarter of 2025 was $7.4 million, an increase of $5.2 million versus the first quarter of 2024.

    Basic and diluted EPS were $(0.09) and adjusted diluted EPS[1] was $0.27 for the first quarter of 2025. Weighted average shares outstanding for both basic and adjusted diluted EPS was 27.7 million.

    Adjusted EBITDA[1] for the first quarter of 2025 was $17.6 million, or 15.7% of net sales, an increase of $5.1 million or 520 basis points versus the first quarter of 2024.

    Full Year 2025 Continuing Operations Financial Guidance:

    Projected Year Ending December 31, 2025Guidance
    Net Sales$445M to $460M
    Adjusted EBITDA [2]$65M to $70M
    Adjusted EPS[2]$0.80 to $0.95

    [1] This is a non-GAAP financial measure. Refer to "Note on Non-GAAP Financial Measures" and the reconciliations in this release for further information.

    [2] This is a non-GAAP financial measure for which a reconciliation to the most directly comparable GAAP financial measure is not available without unreasonable efforts. Refer to "Forward-Looking Non-GAAP Financial Measures" in this release, which identifies the information that is unavailable without unreasonable efforts and provides additional information. It is probable that this forward-looking non-GAAP financial measure may be materially different from the corresponding GAAP financial measure. 

    Conference Call

    ZimVie will host a conference call today, May 8, 2025, at 4:30 p.m. ET to discuss its first quarter 2025 financial results. To access the call, please register online at https://investor.zimvie.com/events-presentations/event-calendar. A live and archived audio webcast will also be available on this site.

    About ZimVie

    ZimVie is a global life sciences leader in the dental market that develops, manufactures, and delivers a comprehensive portfolio of products and solutions designed to support dental tooth replacement and restoration procedures. From its headquarters in Palm Beach Gardens, Florida, and additional facilities around the globe, ZimVie works to improve smiles, function, and confidence in daily life by offering comprehensive tooth replacement solutions, including trusted dental implants, biomaterials, and digital workflow solutions. As a worldwide leader in this space, ZimVie is committed to advancing clinical science and technology foundational to restoring daily life. For more information about ZimVie, please visit us at www.ZimVie.com. Follow @ZimVie on Twitter, Facebook, LinkedIn, or Instagram.

    Note on Non-GAAP Financial Measures

    This press release includes non-GAAP financial measures that differ from financial measures calculated in accordance with U.S. generally accepted accounting principles ("GAAP"). These non-GAAP financial measures may not be comparable to similar measures reported by other companies and should be considered in addition to, and not as a substitute for, or superior to, other measures prepared in accordance with GAAP.

    Sales change information in this release is presented on a GAAP (reported) basis and on a constant currency basis. Constant currency percentage changes exclude the effects of foreign currency exchange rates. They are calculated by translating current and prior-period sales from Continuing Operations at the same predetermined exchange rate. The translated results are then used to determine year-over-year percentage increases or decreases.

    Net income (loss) and diluted earnings (loss) per share in this release are presented on a GAAP (reported) basis and on an adjusted basis. Adjusted net income (loss) and adjusted diluted earnings (loss) per share exclude the effects of certain items, which are detailed in the reconciliations of these non-GAAP financial measures to the most directly comparable GAAP financial measures presented later in this press release.

    Adjusted EBITDA is a non-GAAP financial measure provided in this release for certain periods and is calculated by excluding certain items from net income (loss) from Continuing Operations on a GAAP basis, as detailed in the reconciliations presented later in this press release. Adjusted EBITDA margin is Adjusted EBITDA divided by net sales from Continuing Operations for the applicable period.

    Adjusted cost of products sold (excluding intangible asset amortization), adjusted R&D and adjusted SG&A (on an actual basis and as a percentage of sales) are non-GAAP financial measures provided in this presentation for certain periods and are calculated by excluding the effects of certain items from cost of products sold (excluding intangible asset amortization), R&D and SG&A, respectively, on a GAAP basis. as detailed in the reconciliations presented later in this presentation.

    Reconciliations of these non-GAAP measures to the most directly comparable GAAP financial measures are included in this press release.

    Management uses non-GAAP financial measures internally to evaluate the performance of the business. Additionally, management believes these non-GAAP measures provide meaningful incremental information to investors to consider when evaluating the performance of the company. Management believes these measures offer the ability to make period-to-period comparisons that are not impacted by certain items that can cause dramatic changes in reported income, but that do not impact the fundamentals of our operations. The non-GAAP measures enable the evaluation of operating results and trend analysis by allowing a reader to better identify operating trends that may otherwise be masked or distorted by these types of items that are excluded from the non-GAAP measures.

    Forward-Looking Non-GAAP Financial Measures

    This press release also includes certain forward-looking non-GAAP financial measures for the year ending December 31, 2025. We calculate forward-looking non-GAAP financial measures based on internal forecasts that omit certain amounts that would be included in GAAP financial measures. We have not provided quantitative reconciliations of these forward-looking non-GAAP financial measures to the most directly comparable forward-looking GAAP financial measures because the excluded items are not available on a prospective basis without unreasonable efforts. For example, the timing of certain transactions is difficult to predict because management's plans may change. In addition, the company believes such reconciliations would imply a degree of precision and certainty that could be confusing to investors. It is probable that these forward-looking non-GAAP financial measures may be materially different from the corresponding GAAP financial measures.

    Cautionary Note Regarding Forward-Looking Statements

    This press release contains forward-looking statements within the meaning of federal securities laws, including, among others, any statements about our expectations, plans, intentions, strategies, or prospects. We generally use the words "may," "will," "expects," "believes," "anticipates," "plans," "estimates," "projects," "assumes," "guides," "targets," "forecasts," "sees," "seeks," "should," "could," "would," "predicts," "potential," "strategy," "future," "opportunity," "work toward," "intends," "guidance," "confidence," "positioned," "design," "strive," "continue," "track," "look forward to," "optimistic" and similar expressions to identify forward-looking statements. All statements other than statements of historical or current fact are or may be deemed to be forward-looking statements. Such statements are based upon the current beliefs, expectations, and assumptions of management and are subject to significant risks, uncertainties, and changes in circumstances that could cause actual outcomes and results to differ materially from the forward-looking statements. These risks, uncertainties and changes in circumstances include, but are not limited to: dependence on new product development, technological advances and innovation; shifts in the product category or regional sales mix of our products and services; supply and prices of raw materials and products, including impacts from tariffs; pricing pressures from competitors, customers, dental practices and insurance providers; changes in customer demand for our products and services caused by demographic changes or other factors; challenges relating to changes in and compliance with governmental laws and regulations affecting our U.S. and international businesses, including regulations of the U.S. Food and Drug Administration and foreign government regulators, such as more stringent requirements for regulatory clearance of products; competition; the impact of healthcare reform measures; reductions in reimbursement levels by third-party payors; cost containment efforts sponsored by government agencies, legislative bodies, the private sector and healthcare group purchasing organizations, including the volume-based procurement process in China; control of costs and expenses; dependence on a limited number of suppliers for key raw materials and outsourced activities; the ability to obtain and maintain adequate intellectual property protection; breaches or failures of our information technology systems or products, including by cyberattack, unauthorized access or theft; the ability to retain the independent agents and distributors who market our products; our ability to attract, retain and develop the highly skilled employees we need to support our business; the effect of mergers and acquisitions on our relationships with customers, suppliers and lenders and on our operating results and businesses generally; a determination by the Internal Revenue Service that the distribution of our shares of common stock by Zimmer Biomet Holdings, Inc. in 2022 (the "distribution") or certain related transactions should be treated as taxable transactions; the ability to form and implement alliances; changes in tax obligations arising from tax reform measures, including European Union rules on state aid, or examinations by tax authorities; product liability, intellectual property and commercial litigation losses; changes in general industry and market conditions, including domestic and international growth rates; changes in general domestic and international economic conditions, including inflation and interest rate and currency exchange rate fluctuations; the effects of global pandemics and other adverse public health developments on the global economy, our business and operations and the business and operations of our suppliers and customers, including the deferral of elective procedures and our ability to collect accounts receivable; and the impact of the ongoing financial and political uncertainty on countries in the Euro zone on the ability to collect accounts receivable in affected countries. You are cautioned not to rely on these forward-looking statements, since there can be no assurance that these forward-looking statements will prove to be accurate. Forward-looking statements speak only as of the date they are made, and we expressly disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

    Media Contact Information:

    ZimVie

    Grace Flowers • [email protected]

    (561) 319-6130

    Investor Contact Information:

    Gilmartin Group LLC

    Webb Campbell • [email protected]

    ZIMVIE INC.

    CONSOLIDATED STATEMENT OF OPERATIONS

    (in thousands, except per share data)

    (unaudited)
      
      
     For the Three Months

    Ended March 31,
      2025   2024 
    Net Sales$    111,997  $    118,195 
    Cost of products sold, excluding intangible asset amortization (37,949)  (44,258)
    Intangible asset amortization (6,032)  (6,022)
    Research and development (5,371)  (6,701)
    Selling, general and administrative (58,984)  (60,330)
    Restructuring and other cost reduction initiatives (1,432)  (2,579)
    Acquisition, integration, divestiture and related          (1,449)  (1,037)
    Operating expenses    (111,217)      (120,927)
    Operating Profit (Loss)        780   (2,732)
    Other income (expense), net          1,686            (311)
    Interest income 2,035   507 
    Interest expense (4,052)  (4,873)
    Income (loss) from continuing operations before income taxes                       449   (7,409)
    Provision for income taxes from continuing operations (3,074)  (4,074)
    Net Loss from Continuing Operations of ZimVie Inc. (2,625)  (11,483)
    Income from discontinued operations, net of tax           1,154              3,722 
    Net Loss of ZimVie Inc.$     (1,471) $(7,761)
        
    Basic (Loss) Earnings Per Common Share:   
    Continuing operations$        (0.09) $(0.42)
    Discontinued operations 0.04        0.13   
    Net Loss$        (0.05) $(0.29)
        
    Diluted (Loss) Earnings Per Common Share   
    Continuing operations$         (0.09) $(0.42)
    Discontinued operations 0.04          0.13   
    Net Loss$       (0.05) $(0.29)
        



    ZIMVIE INC.

    CONSOLIDATED BALANCE SHEETS

    (in thousands, except per share data)

    (unaudited)
      
     As of

     March 31, 2025 December 31, 2024
    ASSETS   
    Current Assets:   
    Cash and cash equivalents$66,750  $74,974 
    Accounts receivable, net of allowance for credit losses of $1,985 and $2,088, respectively                         76,688   65,211 
    Inventories 77,675   75,018 
    Prepaid expenses and other current assets 17,309   23,295 
    Current assets of discontinued operations               12,236   18,787 
    Total Current Assets 250,658   257,285 
    Property, plant and equipment, net of accumulated depreciation of $130,816 and $126,620, respectively

                             46,948                           47,268 
    Goodwill              260,444   257,605 
    Intangible assets, net 89,658                92,734 
    Note receivable 65,928   64,643 
    Other assets                  26,298   26,611 
    Noncurrent assets of discontinued operations 5,848                 7,528 
    Total Assets$745,782  $753,674 
    LIABILITIES AND EQUITY   
    Current Liabilities:   
    Accounts payable$31,541  $32,958 
    Income taxes payable 4,139                  3,263 
    Other current liabilities 61,064               62,905 
    Current liabilities of discontinued operations 20,400                  34,818 
    Total Current Liabilities 117,144   133,944 
    Deferred income taxes                    28   — 
    Lease liability 8,237                   8,218 
    Other long-term liabilities 4,631   9,232 
    Non-current portion of debt 220,618   220,451 
    Noncurrent liabilities of discontinued operations                         1   122 
    Total Liabilities 350,659   371,967 
    Commitments and Contingencies    
    Stockholders' Equity:   
    Common stock, $0.01 par value, 150,000 shares authorized Shares, issued and outstanding, of 27,903 and 27,677, respectively 279   277 
    Preferred stock, $0.01 par value, 15,000 shares authorized, 0 shares issued and outstanding —   — 
    Additional paid in capital 940,990   938,630 
    Accumulated deficit (468,110)  (466,639)
    Accumulated other comprehensive loss (78,036)  (90,561)
    Total Stockholders' Equity 395,123   381,707 
    Total Liabilities and Stockholders' Equity$745,782  $753,674 
        



    ZIMVIE INC.

    CONSOLIDATED STATEMENTS OF CASH FLOWS

    (in thousands)

    (unaudited)
     
     For the Three Months Ended March 31,
      2025  2024 
    Cash flows used in operating activities:  
    Net loss of ZimVie Inc.$(1,471)$(7,761)
    Adjustments to reconcile net loss to net cash used in operating activities:  
    Depreciation and amortization                8,655             8,430 
    Share-based compensation                3,497                3,473 
    Deferred income tax provision                 1,012               (233)
    (Gain) loss on disposal of fixed assets (172)                 413 
    Other non-cash items 515               1,596 
    Adjustment of spine disposal group to fair value —            (11,143)
    Changes in operating assets and liabilities:  
    Income taxes 3,722               6,586 
    Accounts receivable (10,019)             (6,651)
    Inventories (1,283)               4,588 
    Prepaid expenses and other current assets 3,360                   323 
    Accounts payable and accrued liabilities (20,386)           (10,264)
    Other assets and liabilities (1,341)                (868)
    Net cash used in operating activities (13,911) (11,511)
    Cash flows used in investing activities:  
    Additions to instruments —             (1,316)
    Additions to other property, plant and equipment (1,503)               (835)
    Other investing activities (444)             (1,987)
    Net cash used in investing activities (1,947) (4,138)
    Cash flows used in financing activities:  
    Payments related to tax withholding for share-based compensation (1,135)            (1,437)
    Net cash used in financing activities (1,135) (1,437)
    Effect of exchange rates on cash and cash equivalents 7,171              (2,098)
    Decrease in cash and cash equivalents (9,822) (19,184)
    Cash and cash equivalents, beginning of year 76,572              87,768 
    Cash and cash equivalents, end of period$66,750 $       68,584 
    Presentation includes cash of both continuing and discontinued operations  
       

    RECONCILIATION OF CONSTANT CURRENCY NET SALES

    Continuing Operations ($ in thousands)

     For the Three Months

    Ended March 31,

         
      2025  2024 Change (%) Foreign Exchange ImpactConstant Currency % Change
    United States$65,833 $67,748 (2.8%) 0.0%(2.8%)
    International 46,164  50,447 (8.5%) (2.6%)(5.9%)
    Total Net Sales$111,997 $118,195 (5.2%) (1.1%)(4.1%)
             

    RECONCILIATION OF ADJUSTED NET INCOME AND DILUTED EPS

    Continuing Operations (in thousands, except per share data)

     For the Three Months Ended March 31, 2025
     Net SalesCost of products sold, excluding intangible asset amortizationOperating expenses, excluding cost of products soldOperating Income Net (Loss) Income Diluted EPS
    Reported$   111,997$(37,949)$(73,268)$780$    (2,625)$      (0.09)
    Restructuring and other cost reduction initiatives [1] - -                1,432              1,432                                1,432  0.05 
    Acquisition, integration, divestiture and related [2] - -                1,449              1,449               1,449  0.05 
    Intangible asset amortization - -                6,032              6,032               6,032  0.22 
    Other charges [3] - 314                        34              348          348              0.01 
    Share-based compensation modification [4] - -                          251                 251            251               0.01 
    Tax effect of above adjustments & other [5] - -  -  - 484  0.02 
    Adjusted$111,997$(37,635)$(64,070)$   10,292$    7,371 $0.27 
           



     For the Three Months Ended March 31, 2024

     Net SalesCost of products sold, excluding intangible asset amortizationOperating expenses, excluding cost of products soldOperating (Loss) IncomeNet (Loss) IncomeDiluted EPS
    Reported$118,195$(44,258)$    (76,669)$(2,732)$        (11,483)$(0.42)
    Restructuring and other cost reduction initiatives [1] - -  2,579  2,579  2,579  0.10 
    Acquisition, integration, divestiture and related [2] - -  1,037  1,037  1,037  0.04 
    Intangible asset amortization - -  6,022  6,022  6,022  0.22 
    European Union medical device regulation [6] - -  401  401  401  0.01 
    Other charges [3] - 286  -  286  286  0.01 
    Tax effect of above adjustments & other [5] - -  -  -  3,316  0.12 
    Adjusted$118,195$(43,972)$(66,630)$7,593 $2,158 $0.08 
           
    [1] Restructuring activities optimize our organization for future success based on the current business environment and sale of the spine business, primarily related to employee termination benefits.
    [2] Acquisition, integration, divestiture and related expenses for the three months ended March 31, 2025 include professional services fees ($0.9 million) and a fair value adjustment of the seller note ($0.3 million), each related to sale of the spine segment, as well as transaction costs related to the evaluation of strategic options for our portfolio ($0.2 million). Acquisition, integration, divestiture and related expenses for the three months ended March 31, 2024 primarily include professional services fees ($0.9 million) related to the sale of the spine segment.
    [3] Regulatory costs incurred in 2025 to change the manufacturer of record as required by our separation from Zimmer Biomet Holdings, Inc. ("ZBH") after initial compliance with the European Union ("EU") Medical Device Regulation ("MDR"), as well as property, plant, and equipment step-up amortization from prior acquisitions.
    [4] Net impact to share-based compensation expense of converting outstanding restricted stock units ("RSUs") with performance-based metrics based on the consolidated results of the spine and dental segments into time-based RSUs following the sale of the spine segment.
    [5] Reflects the tax effect of the adjustments from reported to adjusted, as well as an adjustment for management's expectation of ZimVie's statutory tax rate based on current tax law and adjusted pre-tax income.
    [6] Expenses incurred for initial compliance with the EU MDR for previously-approved products.
     

    RECONCILIATION OF ADJUSTED EBITDA:

    Continuing Operations ($ in thousands)

     



    For the Three Months

    Ended March 31,
      2025   2024 
    Net Sales$111,997  $118,195 
        
    Net Loss$(2,625) $(11,483)
    Interest expense, net 2,017   4,366 
    Income tax provision 3,074   4,074 
    Depreciation and amortization 8,655   8,430 
    EBITDA 11,121   5,387 
    Share-based compensation 3,497   2,762 
    Restructuring and other cost reduction initiatives[1] 1,432   2,579 
    Acquisition, integration, divestiture and related[2] 1,449   1,037 
    European Union medical device regulation[3] —   401 
    Other charges[4] 62   286 
    Adjusted EBITDA$17,561  $12,452 
    Net Loss Margin[5] (2.3%)  (9.7%)
    Adjusted EBITDA Margin[6] 15.7%  10.5%
            



    [1] Restructuring activities to optimize our organization for future success based on the current business environment and sale of the spine business, primarily related to employee termination benefits.

    [2] Acquisition, integration, divestiture and related expenses for the three months ended March 31, 2025 include professional services fees ($0.9 million) and a fair value adjustment of the seller note ($0.3 million), each related to sale of the spine segment, as well as transaction costs related to the evaluation of strategic options for our portfolio ($0.2 million). Acquisition, integration, divestiture and related expenses for the three months ended March 31, 2024 primarily include professional services fees ($0.9 million) related to the sale of the spine segment.
    [3] Expenses incurred for initial compliance with the EU MDR for previously-approved products.
    [4] Regulatory costs incurred in 2025 to change the manufacturer of record as required by our separation from ZBH after initial compliance with the EU MDR, as well as property, plant, and equipment step-up amortization from prior acquisitions.
    [5] Net Loss Margin is calculated as Net Loss divided by Net Sales for the applicable period.
    [6] Adjusted EBITDA Margin is Adjusted EBITDA divided by Net Sales for the applicable period.
     

    RECONCILIATION OF COST OF PRODUCTS SOLD (excluding intangible asset amortization), R&D and SG&A:

    Continuing Operations ($ in thousands)

     Three Months Ended

    March 31,

     Percentage of

    Net Sales
      2025   2024  2025  2024 
    Cost of products sold, excluding intangible asset amortization$(37,949) $(44,258) (33.9%) (37.4%)
    Other charges[1] 314   286  0.3% 0.2%
    Adjusted cost of products sold, excluding intangible asset amortization$(37,635) $(43,972) (33.6%) (37.2%)
            
            
      2025   2024  2025  2024 
    Research and development$(5,371) $(6,701) (4.8%) (5.7%)
    European Union medical device regulation[2] -   401  0.0% 0.4%
    Adjusted research and development$(5,371) $(6,300) (4.8%) (5.3%)
            
            
      2025   2024  2025  2024 
    Selling, general and administrative$(58,984) $(60,330) (52.7%) (51.0%)
    Other charges[1] 34   -  0.0% 0.0%
    Share-based compensation modification[3] 251   -  0.3% 0.0%
    Adjusted selling, general and administrative$(58,699) $(60,330) (52.4%) (51.0%)
     
    [1] Regulatory costs incurred in 2025 to change the manufacturer of record as required by our separation from ZBH after initial compliance with the EU MDR, as well as property, plant, and equipment step-up amortization from prior acquisitions.
    [2] Expenses incurred for initial compliance with the EU MDR for previously-approved products.
    [3] Net impact to share-based compensation expense of converting outstanding RSUs with performance-based metrics based on the consolidated results of the spine and dental segments to time-based RSUs following the sale of the spine segment.


    Primary Logo

    Get the next $ZIMV alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ZIMV

    DatePrice TargetRatingAnalyst
    4/10/2025$16.00Buy
    B. Riley Securities
    3/13/2025Buy → Hold
    Needham
    5/16/2024$20.00Hold → Buy
    Needham
    11/16/2023Hold
    Needham
    12/21/2022$9.00Underweight
    Barclays
    6/17/2022$20.00Neutral
    JP Morgan
    3/18/2022Neutral
    Guggenheim
    More analyst ratings

    $ZIMV
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • B. Riley Securities initiated coverage on ZimVie with a new price target

      B. Riley Securities initiated coverage of ZimVie with a rating of Buy and set a new price target of $16.00

      4/10/25 12:44:28 PM ET
      $ZIMV
      Medical/Dental Instruments
      Health Care
    • ZimVie downgraded by Needham

      Needham downgraded ZimVie from Buy to Hold

      3/13/25 7:58:34 AM ET
      $ZIMV
      Medical/Dental Instruments
      Health Care
    • ZimVie upgraded by Needham with a new price target

      Needham upgraded ZimVie from Hold to Buy and set a new price target of $20.00

      5/16/24 7:42:36 AM ET
      $ZIMV
      Medical/Dental Instruments
      Health Care

    $ZIMV
    SEC Filings

    See more
    • SEC Form 10-Q filed by ZimVie Inc.

      10-Q - ZimVie Inc. (0001876588) (Filer)

      5/8/25 4:15:20 PM ET
      $ZIMV
      Medical/Dental Instruments
      Health Care
    • ZimVie Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure

      8-K - ZimVie Inc. (0001876588) (Filer)

      5/8/25 4:10:42 PM ET
      $ZIMV
      Medical/Dental Instruments
      Health Care
    • SEC Form DEFA14A filed by ZimVie Inc.

      DEFA14A - ZimVie Inc. (0001876588) (Filer)

      3/25/25 8:05:36 AM ET
      $ZIMV
      Medical/Dental Instruments
      Health Care

    $ZIMV
    Financials

    Live finance-specific insights

    See more
    • ZimVie Reports First Quarter 2025 Financial Results

      Net Sales from Continuing Operations of $112.0 millionNet Loss from Continuing Operations of $(2.6) million; Net Loss margin of (2.3)% Adjusted EBITDA[1] from Continuing Operations of $17.6 million; Adjusted EBITDA[1] margin of 15.7%GAAP diluted EPS from Continuing Operations of $(0.09) and adjusted diluted EPS[1] from Continuing Operations of $0.27 PALM BEACH GARDENS, Fla., May 08, 2025 (GLOBE NEWSWIRE) -- ZimVie Inc. (NASDAQ:ZIMV), a global life sciences leader in the dental market, today reported financial results for the quarter ended March 31, 2025. Management will host a corresponding conference call today, May 8, 2025, at 4:30 p.m. Eastern Time. "We are proud to have entered 2025

      5/8/25 4:05:00 PM ET
      $ZIMV
      Medical/Dental Instruments
      Health Care
    • ZimVie to Report First Quarter 2025 Financial Results on May 8, 2025

      PALM BEACH GARDENS, Fla., April 24, 2025 (GLOBE NEWSWIRE) -- ZimVie Inc. (NASDAQ:ZIMV), a global life sciences leader in the dental market, today announced it will report financial results for the first quarter 2025 after market close on Thursday, May 8, 2025. Company management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time. Those interested in listening to the conference call should register online here. Participants are encouraged to register more than 15 minutes before the start of the call. A replay of the webcast will be available at investor.zimvie.com About ZimVie ZimVie is a global life sciences leader in the dental market that develops, manufactu

      4/24/25 4:05:00 PM ET
      $ZIMV
      Medical/Dental Instruments
      Health Care
    • ZimVie Reports Fourth Quarter and Full Year 2024 Financial Results

      FY2024 Third Party Net Sales from Continuing Operations of $449.7 millionFY2024 Net Loss from Continuing Operations of $(33.8) million; Net Loss margin of (7.5%) FY2024 Adjusted EBITDA[1] from Continuing Operations of $60.0 million; Adjusted EBITDA[1] margin of 13.3%FY2024 GAAP diluted EPS from Continuing Operations of $(1.23) and adjusted diluted EPS[1] of $0.62 PALM BEACH GARDENS, Fla., Feb. 26, 2025 (GLOBE NEWSWIRE) -- ZimVie Inc. (NASDAQ:ZIMV), a global life sciences leader in the dental market, today reported financial results for the quarter and year ended December 31, 2024. Management will host a corresponding conference call today, February 26, 2025, at 4:30 p.m. Eastern Time. "2

      2/26/25 4:05:00 PM ET
      $ZIMV
      Medical/Dental Instruments
      Health Care

    $ZIMV
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Officer Jamali Vafa converted options into 21,331 shares and covered exercise/tax liability with 9,333 shares, increasing direct ownership by 3% to 360,257 units (SEC Form 4)

      4 - ZimVie Inc. (0001876588) (Issuer)

      4/3/25 4:03:34 PM ET
      $ZIMV
      Medical/Dental Instruments
      Health Care
    • SEC Form 4 filed by Director Kuntz Richard

      4 - ZimVie Inc. (0001876588) (Issuer)

      4/2/25 5:22:27 PM ET
      $ZIMV
      Medical/Dental Instruments
      Health Care
    • SEC Form 4 filed by Director King David P

      4 - ZimVie Inc. (0001876588) (Issuer)

      4/2/25 4:47:15 PM ET
      $ZIMV
      Medical/Dental Instruments
      Health Care

    $ZIMV
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • ZimVie Reports First Quarter 2025 Financial Results

      Net Sales from Continuing Operations of $112.0 millionNet Loss from Continuing Operations of $(2.6) million; Net Loss margin of (2.3)% Adjusted EBITDA[1] from Continuing Operations of $17.6 million; Adjusted EBITDA[1] margin of 15.7%GAAP diluted EPS from Continuing Operations of $(0.09) and adjusted diluted EPS[1] from Continuing Operations of $0.27 PALM BEACH GARDENS, Fla., May 08, 2025 (GLOBE NEWSWIRE) -- ZimVie Inc. (NASDAQ:ZIMV), a global life sciences leader in the dental market, today reported financial results for the quarter ended March 31, 2025. Management will host a corresponding conference call today, May 8, 2025, at 4:30 p.m. Eastern Time. "We are proud to have entered 2025

      5/8/25 4:05:00 PM ET
      $ZIMV
      Medical/Dental Instruments
      Health Care
    • ZimVie to Report First Quarter 2025 Financial Results on May 8, 2025

      PALM BEACH GARDENS, Fla., April 24, 2025 (GLOBE NEWSWIRE) -- ZimVie Inc. (NASDAQ:ZIMV), a global life sciences leader in the dental market, today announced it will report financial results for the first quarter 2025 after market close on Thursday, May 8, 2025. Company management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time. Those interested in listening to the conference call should register online here. Participants are encouraged to register more than 15 minutes before the start of the call. A replay of the webcast will be available at investor.zimvie.com About ZimVie ZimVie is a global life sciences leader in the dental market that develops, manufactu

      4/24/25 4:05:00 PM ET
      $ZIMV
      Medical/Dental Instruments
      Health Care
    • ZimVie Pioneers the Future of Molar Restoration with New Immediate Molar Dental Implant System

      PALM BEACH GARDENS, Fla., April 21, 2025 (GLOBE NEWSWIRE) -- ZimVie Inc. (NASDAQ:ZIMV), a global life sciences leader in the dental implant market, today announced the launch of its Immediate Molar Implant System in the United States. ZimVie is expanding its already clinically proven TSX® and T3 PRO® Implant systems with an immediate molar solution, simplifying challenging clinical scenarios for providers and shortening treatment times for patients requiring molar implants. Immediately replacing extracted molars with an implant can be difficult due to the complex multi-rooted anatomy and size of the tooth socket. ZimVie's Immediate Molar Implant System includes specially engineered instru

      4/21/25 8:00:00 AM ET
      $ZIMV
      Medical/Dental Instruments
      Health Care

    $ZIMV
    Leadership Updates

    Live Leadership Updates

    See more
    • ZimVie Announces Upcoming Changes to Company's Board of Directors

      PALM BEACH GARDENS, Fla., March 13, 2025 (GLOBE NEWSWIRE) -- ZimVie Inc. (NASDAQ:ZIMV), a global life sciences leader in the dental implant market, today announced upcoming changes to the Company's Board of Directors, including:  Non-Executive Chair David King will not stand for reelection as a director upon the expiration of his current term at the Company's annual meeting of shareholders on May 7, 2025.President and CEO Vafa Jamali will be appointed Chairman of the Board effective as of May 7, 2025.Director Vinit Asar will be appointed Lead Independent Director effective upon the commencement of Mr. Jamali's service as Chairman. Retirement of Mr. King "On behalf of ZimVie and our Boar

      3/13/25 4:15:00 PM ET
      $ZIMV
      Medical/Dental Instruments
      Health Care
    • Veradigm Announces Board Expansion and Changes

      Appoints Vinit Asar and Louis Silverman to its Board of Directors Agrees to Add Two Additional Directors Veradigm® (OTC:MDRX) ("Veradigm" or the "Company"), a leading provider of healthcare data and technology solutions, announced today it has entered into a Cooperation Agreement (the "Agreement") with Kent Lake PR LLC ("Kent Lake"). The Agreement aligns with the Board's request for input from shareholders regarding board composition on January 30, 2025, and a desire to conduct an orderly refreshment of the Board following the conclusion of the exploration of strategic alternatives. As part of the Agreement, the Board has appointed two new independent directors, Vinit Asar and Louis Silve

      2/20/25 4:02:00 PM ET
      $MDRX
      $OCX
      $ZIMV
      EDP Services
      Technology
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $ZIMV
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by ZimVie Inc.

      SC 13G - ZimVie Inc. (0001876588) (Subject)

      11/14/24 4:11:11 PM ET
      $ZIMV
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13G/A filed by ZimVie Inc.

      SC 13G/A - ZimVie Inc. (0001876588) (Subject)

      11/14/24 10:58:06 AM ET
      $ZIMV
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13G/A filed by ZimVie Inc.

      SC 13G/A - ZimVie Inc. (0001876588) (Subject)

      10/4/24 1:02:25 PM ET
      $ZIMV
      Medical/Dental Instruments
      Health Care